Clinical Trials Browser

Phase 2 × Octreotide × Gastrointestinal × Clear all

Esophageal Neoplasms, Stomach Neoplasms, Weight Loss

NCT06085976 2023-10-17

Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.

Phase 2 Unknown

62 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT00004895 2012-06-06

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

Phase 2 Completed

GastrointestinalGynecologicOtherSarcoma

Carcinoma, Ovarian Epithelial, Bile Duct Neoplasms, Colonic Neoplasms, Constipation, Intestinal Obstruction, Nausea, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Vomiting, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT00257426 2012-02-14

Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Phase 2 Completed

31 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00250796 2010-01-07

Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma

Phase 2 Completed

12 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

Clinical Trials

OTIS

Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma